Alvotech (ALVO) is a Healthcare · Drug Manufacturers - Specialty & Generic company listed on NASDAQ. Price $5.87 (+9.93%), Market cap $1.12B, P/E ratio 35.90, 52-week low–high $3.11 ~ $11.45.
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosi
Financial statements, price targets, institutional (13F) holdings and related news for Alvotech are updated in real time on BlackAll Trade.
Alvotech trades at $5.87 (+9.93%). Real-time quotes and charts are available on BlackAll Trade.
Alvotech has a market cap of about $1.12B. Its P/E ratio is 35.90.
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders